|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2001
Evaluation of bronchodilator responses in patients with "irreversible" emphysema
Respiratory Investigation Unit, Dept of Medicine, Queen's University, Kingston, Ontario, Canada
CORRESPONDENCE: D.E. O'Donnell, Richardson House, 102 Stuart Street, c/o Kingston General Hospital, Kingston, Ontario, Canada, K7L 2V7. Fax: 1 6135491459
Keywords: Bronchodilators, chronic obstructive pulmonary disease, emphysema, inspiratory capacity, lung hyperinflation, reversibility criteria
Received: February 19, 2001
Accepted July 11, 2001
This work was supported by the Ontario Ministry of Health.
Given the emerging physiological and clinical rationale for pharmacological lung-volume reduction, assessment of volume responses to bronchodilators is likely to be highly relevant in chronic obstructive pulmonary disease (COPD). The authors examined the magnitude of lung-volume reduction after acute bronchodilator treatment in patients with advanced emphysema.
Eighty-four stable patients with emphysema (mean±sem forced expiratory volume in one second (FEV1): 32±1% predicted) performed spirometry and body plethysmography before and 15–30 min after 200 µg salbutamol. Only irreversible patients with a postbronchodilator change in FEV1 <10% pred were considered in this study.
Postsalbutamol, the majority of subjects (83%) had significant improvements in one or more lung volumes: on average, residual volume (RV), functional residual capacity (FRC), inspiratory capacity (IC), forced vital capacity and slow vital capacity changed by –18±2, –10±1, 8±1, 9±1 and 7±1% pred (p<0.0005 each). Total lung capacity (TLC) decreased 0.12±0.04 L (p<0.01). Change in IC reflected change in FRC (r=–0.60, p<0.0005), but more strongly in the 57% of patients with no significant change in TLC (r=–0.93, p<0.0005). The magnitude and frequency of volume responses were greatest in patients with the most severe COPD; for example, RV decreased by 0.51±0.09 L (23±4% pred) and 0.27±0.04 L (14±2% pred) in severe and moderate subgroups, respectively.
Significant reductions in lung hyperinflation occurred in the absence of a change in forced expiratory volume in one second after low-dose salbutamol in a majority of patients with advanced emphysema; the greatest changes occurred in those with the most severe disease.
This article has been cited by other articles:
|
|
 |
|
  D E O'Donnell, P Laveneziana, J Ora, K A Webb, Y-M Lam, and D Ofir Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD Thorax, March 1, 2009; 64(3): 216 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. O'Donnell, R. B. Banzett, V. Carrieri-Kohlman, R. Casaburi, P. W. Davenport, S. C. Gandevia, A. F. Gelb, D. A. Mahler, and K. A. Webb Pathophysiology of Dyspnea in Chronic Obstructive Pulmonary Disease: A Roundtable Proceedings of the ATS, May 1, 2007; 4(2): 145 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sharafkhaneh, T. G. Babb, T. M. Officer, N. A. Hanania, H. Sharafkhaneh, and A. M. Boriek The Confounding Effects of Thoracic Gas Compression on Measurement of Acute Bronchodilator Response Am. J. Respir. Crit. Care Med., February 15, 2007; 175(4): 330 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. O'Donnell and P. Laveneziana Lung hyperinflation in COPD: the impact of pharmacotherapy Eur. Respir. Rev., December 1, 2006; 15(100): 85 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. F. M. Wouters Approaches to Improving Health Status in Chronic Obstructive Pulmonary Disease: One or Several? Proceedings of the ATS, May 1, 2006; 3(3): 262 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. O'Donnell Is Sustained Pharmacologic Lung Volume Reduction Now Possible in COPD? Chest, March 1, 2006; 129(3): 501 - 503. [Full Text] [PDF]
|
|
|
|
 |
|
 Beta2 agonist reversibility testing in COPD diagnosis DTB, December 1, 2005; 43(12): 89 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Bateman Improving inhaler use in COPD and the role of patient preference Eur. Respir. Rev., December 1, 2005; 14(96): 85 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Rodriguez-Roisin Is this the beginning of unravelling the puzzle of COPD exacerbations? Eur. Respir. J., September 1, 2005; 26(3): 376 - 378. [Full Text] [PDF]
|
|
|
|
|
|
C. M. Parker, N. Voduc, S. D. Aaron, K. A. Webb, and D. E. O'Donnell Physiological changes during symptom recovery from moderate exacerbations of COPD Eur. Respir. J., September 1, 2005; 26(3): 420 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nair, E. Thomas, S. B. Pearson, and M. T. Henry A Randomized Controlled Trial To Assess the Optimal Dose and Effect of Nebulized Albuterol in Acute Exacerbations of COPD Chest, July 1, 2005; 128(1): 48 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. I. Rennard Clinical Approach to Patients with Chronic Obstructive Pulmonary Disease and Cardiovascular Disease Proceedings of the ATS, April 1, 2005; 2(1): 94 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. C. Sciurba Physiologic Similarities and Differences Between COPD and Asthma Chest, August 1, 2004; 126(2_suppl_1): 117S - 124S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.E. O'Donnell, N. Voduc, M. Fitzpatrick, and K.A. Webb Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease Eur. Respir. J., July 1, 2004; 24(1): 86 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.E. O'Donnell, T. Fluge, F. Gerken, A. Hamilton, K. Webb, B. Aguilaniu, B. Make, and H. Magnussen Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD Eur. Respir. J., June 1, 2004; 23(6): 832 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Cerveri, R. Dore, A. Corsico, M. C. Zoia, R. Pellegrino, V. Brusasco, and E. Pozzi Assessment of Emphysema in COPD: A Functional and Radiologic Study Chest, May 1, 2004; 125(5): 1714 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J P Fuldl and M M Cotton Performance enhancement in chronic obstructive pulmonary disease Chronic Respiratory Disease, April 1, 2004; 1(2): 95 - 98. [Abstract] [PDF]
|
|
|
|
|
|
R.O. Crapo, R.L. Jensen, and F.E. Hargreave Airway inflammation in COPD: physiological outcome measures and induced sputum Eur. Respir. J., June 1, 2003; 21(41_suppl): 19S - 28s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Di Marco, J. Milic-Emili, B. Boveri, P. Carlucci, P. Santus, F. Casanova, M. Cazzola, and S. Centanni Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD Eur. Respir. J., January 1, 2003; 21(1): 86 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Diaz, P. Begin, B. Torrealba, E. Jover, and C. Lisboa Effects of noninvasive ventilation on lung hyperinflation in stable hypercapnic COPD Eur. Respir. J., December 1, 2002; 20(6): 1490 - 1498. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |